Invenomic Capital Management’s 8x8 Inc EGHT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.4M Sell
818,755
-1,102,420
-57% -$2.22M 0.08% 108
2026
Q1
$3.19M Sell
1,921,175
-1,169,304
-38% -$2.39M 0.15% 117
2025
Q4
$6.09M Sell
3,090,479
-70,234
-2% -$138K 0.28% 102
2025
Q3
$6.7M Sell
3,160,713
-168,940
-5% -$340K 0.32% 86
2025
Q2
$6.53M Sell
3,329,653
-505,711
-13% -$893K 0.37% 85
2025
Q1
$7.67M Sell
3,835,364
-1,352,184
-26% -$3.48M 0.39% 88
2024
Q4
$13.9M Sell
5,187,548
-340,949
-6% -$875K 0.66% 46
2024
Q3
$11.3M Buy
5,528,497
+524,580
+10% +$1.16M 0.62% 58
2024
Q2
$11.1M Buy
5,003,917
+2,354,895
+89% +$5.73M 0.54% 64
2024
Q1
$7.15M Buy
2,649,022
+571,245
+27% +$1.73M 0.38% 84
2023
Q4
$7.85M Buy
2,077,777
+990,352
+91% +$2.94M 0.36% 83
2023
Q3
$2.74M Buy
1,087,425
+158,755
+17% +$564K 0.12% 115
2023
Q2
$3.93M Buy
+928,670
New +$3.35M 0.2% 93

Other funds holding EGHT

Invenomic Capital Management's EGHT Position: Q2 2026 in Review

Invenomic Capital Management reduced its 8x8 Inc (EGHT) stake by 57% in Q2 2026, selling an estimated $2.22M and leaving 818,755 shares worth $1.4M. The position accounts for 0.08% of the portfolio, ranked #108.

Invenomic Capital Management first reported a position in EGHT in Q2 2023 and has held it in 13 quarters since. The position peaked at $13.9M in Q4 2024. 173 funds tracked by Wall St. Rank hold EGHT as of Q2 2026.

  • Invenomic Capital Management held 818,755 shares of 8x8 Inc worth $1.4M as of Q2 2026.
  • Invenomic Capital Management sold 1,102,420 8x8 Inc shares in Q2 2026, an estimated $2.22M.
  • 8x8 Inc made up 0.08% of Invenomic Capital Management's portfolio in Q2 2026, its #108 holding.
  • Invenomic Capital Management first reported a position in 8x8 Inc in Q2 2023 and has held it in 13 quarters since.
  • Invenomic Capital Management's 8x8 Inc position peaked at $13.9M in Q4 2024.
  • 173 funds tracked by Wall St. Rank held 8x8 Inc as of Q2 2026.

Based on Invenomic Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.